| Measure Type | High Priority Measure? | Collection Type(s) |
|---|---|---|
| Process | no | MIPS CQM |
Measure Description
Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy for whom RAS (KRAS and NRAS) gene mutation testing was performed